Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BrainCool AB is a prominent company engaged in the development and commercialization of advanced medical cooling technologies. These innovations primarily focus on therapeutic hypothermia, aiming to improve patient outcomes in critical care scenarios such as cardiac arrest, stroke, and traumatic brain injuries. The company's product line includes portable systems suitable for both hospital and pre-hospital settings, ensuring timely intervention in emergency situations. BrainCool’s offerings are a testament to its commitment to enhancing the quality of patient care and extending survival rates through non-invasive cooling techniques. Established in the healthcare and biotechnology sectors, BrainCool's solutions are pivotal in therapeutic areas where rapid temperature management can be crucial. Based in Sweden, the company plays a vital role in the medical technology industry, driving advancements that align with global health initiatives to address cardiovascular and neurological conditions. With an emphasis on research and development, BrainCool AB is continually working to refine its technologies and expand their applicability across various medical settings.
kr 0.05
+kr 0.00 (+5.74%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-95.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 9.4% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -kr 59M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 42M
▼ -9.4% YoY
Net Income (TTM)
-kr 37M
▲ +15.9% YoY
Op. Margin
-83.97%
▲ +10.5pp YoY
ROIC
-16.92%
▲ +9.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 54M
▲ +15.7% YoY
Op. Cash Flow (TTM)
-kr 46M
▲ +9.4% YoY
Net Debt
-kr 40M
Net Cash Position
Cash & Equiv.
kr 40M
3Y CAGR: +27.2%
Continue Research
BrainCool AB (BRAIN.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BrainCool AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
BrainCool AB scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -84.0% operating margin and a -16.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BRAIN.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.